We conducted a search for rare, functional variants altering susceptibility to Alzheimer's disease that exploited knowledge of common variants associated with the same disease. We found that loss-of-function variants in ABCA7 confer risk of Alzheimer's disease in Icelanders (odds ratio (OR) = 2.12, P = 2.2 × 10 −13 ) and discovered that the association replicated in study groups from Europe and the United States (combined OR = 2.03, P = 6.8 × 10 −15 ).
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Alzheimer's disease is a common neurodegenerative disorder with high heritability. The ε4 allele of APOE was found to associate with Alzheimer's disease about 20 years ago 1, 2 , and rare variants in three genes (APP, PSEN1 and PSEN2) were implicated in familial, earlyonset forms of the disease around the same time 3 . More recently, rare variants in APP and TREM2 were discovered to affect susceptibility to the sporadic, late-onset form of Alzheimer's disease [4] [5] [6] , and the latest meta-analysis of common variants demonstrated that 19 loci, in addition to the APOE locus, harbor variants showing genome-wide significant association with Alzheimer's disease 7 . The new common variant association regions include the major histocompatibility complex (MHC) locus and 18 other regions in which the association signal extends over 104 genes (summarized in Supplementary Table 1) 7 .
We used our imputation of the whole-genome sequences of 2,636 Icelanders into 104,220 long-range phased individuals and their close relatives 8 to investigate whether any of the genes located in the regions showing common variant association with Alzheimer's disease (excluding the MHC) also harbored rare variants conferring higher risk. We considered two classes of variants: nonsense, frameshift or canonical splice-site variants ('loss of function'), and missense or splice-site variants ('missense'). Because loss-of-function mutations are likely to have the same biological effect-no protein is produced as a result of nonsense-mediated decay of mRNA containing premature stop codons-we collapsed these variants into a single allele and estimated one effect. Missense variants may have different biological consequences; thus, for these variants, we ran analyses using SKAT 9 , a gene test that allows different effects, in addition to a collapsing test.
We carried out association testing using information from 3,419 individuals with Alzheimer's disease and 151,805 population controls. For loss-of-function variants, collapsing tests using variants with minor allele frequency (MAF) <0.5% and information >0.8 resulted in examination of 20 genes in 10 common variant association regions. The most significant association result was for ABCA7 (OR = 2.08, P = 3.8 × 10 −5 ) (Supplementary Table 2 ). For missense variants, we carried out collapsing tests for variants with MAF <0.5% and information >0.8 (79 genes in 17 regions), and SKAT scans using both all variants with MAF <1% and information >0.8 (82 genes in 17 regions) and the subset of those variants predicted to be damaging or possibly damaging by PolyPhen (63 genes in 17 regions). The most significant result for the missense variant tests was for ABCA7, obtained using SKAT with all variants (P = 0.00020; Supplementary Tables 3 and 4).
As the most significant result for both the loss-of-function and missense variant scans was for ABCA7, we searched for functional commonality among the variants producing significance in the two scans. We found that the ABCA7 missense variant test was significant due to a single splice-site variant, c.5570+5G>C (P = 0.46 without this variant). Examination of transcripts from several c.5570+5G>C carriers using RNA sequencing (RNA-seq) showed that this variant led to mRNA containing intronic sequences ( Supplementary  Fig. 1 ) that eventually included a stop codon. Thus, c.5570+5G>C
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We followed up the ABCA7 loss-of-function association result further by carrying out Sanger sequencing of predicted variant carriers to validate the variants and to create a larger reference set for reimputation. Five of the six variants included in the original loss-of-function test as well as c.5570+5G>C and two variants not included in the initial scan because of low information scores were validated. All pairs of variants were uncorrelated (r 2 < 0.001). Each of the variants was predicted to cause the insertion of a stop codon into the transcript before the last two exons. After reimputation, ABCA7 loss-of-function variants were associated with Alzheimer's disease with an OR of 2.12 and a P value of 2.2 × 10 −13 ( Table 1) .
Using our long-range phased haplotypes, we found that the ABCA7 loss-of-function variants were never located on the background of rs4147929[A], the common variant previously associated with Alzheimer's disease 7 . Thus, the loss-of-function variant association described here could not account for the common variant association, nor vice versa. We did not find evidence of interaction between the rare ABCA7 loss-of-function alleles and rs4147929[A] (P = 0.35).
To investigate the effect of these variants on Alzheimer's disease outside Iceland, we genotyped the ABCA7 loss-of-function variants in study groups from Finland, Germany, Norway and the United States. We found six of the eight variants in at least one of the study groups (Supplementary Table 5 ). In the combined replication study groups, loss-of-function variants were associated with Alzheimer's disease with an OR of 1.73 and a P value of 0.0056 ( Table 2 and  Supplementary Table 5 ). Meta-analysis with the Icelandic data yielded an OR of 2.03 and a P value of 6.8 × 10 −15 .
ABCA7, or ATP-binding cassette transporter A7, is a member of the A subfamily of ABC transporters that move primarily lipids across membranes 10 . It is strongly expressed in brain, with the highest levels found in microglia 10 . ABCA7 promotes the efflux of phospholipids and cholesterol to apolipoprotein A-I (apoA-I) and apolipoprotein E (apoE) in cell culture 11, 12 . ABCA7 is also an ortholog of the Caenorhabditis elegans gene ced-7, the product of which has a crucial role in the engulfment of apoptotic cells. In line with this function, ABCA7 is involved in the promotion of phagocytosis in several human cell lines 13, 14 .
Recent results from mouse models suggest that the primary function of ABCA7 is in the regulation of phagocytosis rather than in cholesterol metabolism. Abca7-null mice have only modestly altered serum cholesterol levels, and cholesterol and phospholipid efflux in macrophages isolated from these mice does not differ from that of wild-type macrophages 15 . In addition, although J20 Abca7-null mice have greater insoluble amyloid β (Aβ) levels than J20 mice, they do not have elevated apoE concentrations, suggesting that the increase in Aβ levels is not a result of increased efflux to apoE 16 .
To investigate whether genetic data provide any insights into the pathway through which ABCA7 acts, we tested for statistical interaction of the ABCA7 loss-of-function variants with either APOE ε4 or the Alzheimer's disease-associated variant in TREM2, which encodes a protein involved in microglial activation 17, 18 . We found no evidence of interaction of the ABCA7 loss-of-function variants with the Alzheimer's disease-associated alleles of either APOE or TREM2 (P = 0.72 and 0.38, respectively).
This study reinforces the claim that ABCA7, rather than neighboring genes, is involved in the pathogenesis of Alzheimer's disease. In addition, although it is currently unknown how the causal variant tagged by rs4147929[A] affects ABCA7 expression in the brain-both increased and decreased mRNA levels have been reported 19, 20 -our results for the loss-of-function variants suggest that rs4147929[A] is likely to lead to reduced levels of the protein. Moreover, because of the high OR associated with ABCA7 loss-of-function variants, carriers of these variants should be useful participants in clinical studies seeking to improve the understanding and treatment of Alzheimer's disease.
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